CH654591A5 - Verfahren zum nachweis von erregern im blut. - Google Patents
Verfahren zum nachweis von erregern im blut. Download PDFInfo
- Publication number
- CH654591A5 CH654591A5 CH9827/78A CH982778A CH654591A5 CH 654591 A5 CH654591 A5 CH 654591A5 CH 9827/78 A CH9827/78 A CH 9827/78A CH 982778 A CH982778 A CH 982778A CH 654591 A5 CH654591 A5 CH 654591A5
- Authority
- CH
- Switzerland
- Prior art keywords
- blood
- pathogens
- adsorbent
- detection
- polymer
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 56
- 210000004369 blood Anatomy 0.000 title claims description 19
- 239000008280 blood Substances 0.000 title claims description 19
- 244000052769 pathogen Species 0.000 claims description 28
- 239000003463 adsorbent Substances 0.000 claims description 25
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 24
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- 238000001514 detection method Methods 0.000 claims description 12
- 235000015097 nutrients Nutrition 0.000 claims description 12
- 229920000642 polymer Polymers 0.000 claims description 11
- 239000002609 medium Substances 0.000 claims description 10
- 244000052616 bacterial pathogen Species 0.000 claims description 9
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 8
- 230000003115 biocidal effect Effects 0.000 claims description 8
- 238000009640 blood culture Methods 0.000 claims description 8
- 229960002897 heparin Drugs 0.000 claims description 8
- 229920000669 heparin Polymers 0.000 claims description 8
- 239000011521 glass Substances 0.000 claims description 7
- 230000001717 pathogenic effect Effects 0.000 claims description 7
- 206010040047 Sepsis Diseases 0.000 claims description 6
- 230000000721 bacterilogical effect Effects 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 230000002906 microbiologic effect Effects 0.000 claims description 5
- 230000003612 virological effect Effects 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 241000233866 Fungi Species 0.000 claims description 4
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 4
- 238000011068 loading method Methods 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 claims description 3
- 239000011148 porous material Substances 0.000 claims description 3
- 102000009027 Albumins Human genes 0.000 claims description 2
- 108010088751 Albumins Proteins 0.000 claims description 2
- 239000004677 Nylon Substances 0.000 claims description 2
- 239000003146 anticoagulant agent Substances 0.000 claims description 2
- 229940127219 anticoagulant drug Drugs 0.000 claims description 2
- 229920002301 cellulose acetate Polymers 0.000 claims description 2
- 229910010293 ceramic material Inorganic materials 0.000 claims description 2
- 230000004087 circulation Effects 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 238000011534 incubation Methods 0.000 claims description 2
- 229910044991 metal oxide Inorganic materials 0.000 claims description 2
- 150000004706 metal oxides Chemical class 0.000 claims description 2
- 244000005700 microbiome Species 0.000 claims description 2
- 229920001778 nylon Polymers 0.000 claims description 2
- 229920000058 polyacrylate Polymers 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 229920005989 resin Polymers 0.000 claims description 2
- 239000011347 resin Substances 0.000 claims description 2
- 238000004626 scanning electron microscopy Methods 0.000 claims description 2
- 206010037660 Pyrexia Diseases 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 206010058872 Fungal sepsis Diseases 0.000 claims 1
- 206010061217 Infestation Diseases 0.000 claims 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 230000000843 anti-fungal effect Effects 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 201000005008 bacterial sepsis Diseases 0.000 claims 1
- 229920000249 biocompatible polymer Polymers 0.000 claims 1
- 238000004820 blood count Methods 0.000 claims 1
- 230000007123 defense Effects 0.000 claims 1
- 230000014670 detection of bacterium Effects 0.000 claims 1
- 230000010244 detection of fungus Effects 0.000 claims 1
- 230000010460 detection of virus Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims 1
- 238000013399 early diagnosis Methods 0.000 claims 1
- 150000002500 ions Chemical group 0.000 claims 1
- 206010024378 leukocytosis Diseases 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 238000005457 optimization Methods 0.000 claims 1
- 230000000717 retained effect Effects 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 235000012239 silicon dioxide Nutrition 0.000 claims 1
- 230000007480 spreading Effects 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229920003002 synthetic resin Polymers 0.000 claims 1
- 239000000057 synthetic resin Substances 0.000 claims 1
- 239000011800 void material Substances 0.000 claims 1
- 230000001951 hemoperfusion Effects 0.000 description 14
- 239000002775 capsule Substances 0.000 description 12
- 230000010412 perfusion Effects 0.000 description 12
- 239000002245 particle Substances 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
- 239000003245 coal Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000004809 Teflon Substances 0.000 description 3
- 229920006362 Teflon® Polymers 0.000 description 3
- 239000003610 charcoal Substances 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000002965 anti-thrombogenic effect Effects 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013048 microbiological method Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 239000005373 porous glass Substances 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 238000004544 sputter deposition Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940071127 thioglycolate Drugs 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229910001928 zirconium oxide Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/80—Elimination or reduction of contamination by undersired ferments, e.g. aseptic cultivation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/803—Physical recovery methods, e.g. chromatography, grinding
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Toxicology (AREA)
- Virology (AREA)
- External Artificial Organs (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2826416A DE2826416C3 (de) | 1978-06-16 | 1978-06-16 | Vorrichtung zum Nachweis von Bakterien, Pilzen und Viren im Blut |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH654591A5 true CH654591A5 (de) | 1986-02-28 |
Family
ID=6041959
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH9827/78A CH654591A5 (de) | 1978-06-16 | 1978-09-20 | Verfahren zum nachweis von erregern im blut. |
| CH4058/85A CH658376A5 (de) | 1978-06-16 | 1978-09-20 | Vorrichtung zum nachweis von erregern im blut. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH4058/85A CH658376A5 (de) | 1978-06-16 | 1978-09-20 | Vorrichtung zum nachweis von erregern im blut. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US4543328A (enExample) |
| JP (1) | JPS5523986A (enExample) |
| AT (1) | AT363610B (enExample) |
| BE (1) | BE870435A (enExample) |
| CA (1) | CA1248435A (enExample) |
| CH (2) | CH654591A5 (enExample) |
| DK (1) | DK153798C (enExample) |
| FI (1) | FI62138C (enExample) |
| FR (1) | FR2432048A1 (enExample) |
| GB (1) | GB2024421B (enExample) |
| IT (1) | IT1098837B (enExample) |
| NL (1) | NL7809357A (enExample) |
| SE (1) | SE452336B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD149843A3 (de) * | 1979-06-28 | 1981-08-05 | Manfred Kunze | Verfahren und vorrichtung zum nachweis von bakteriaemien |
| JPS5897236U (ja) * | 1981-12-24 | 1983-07-01 | 日精株式会社 | ２段式駐車装置 |
| JPS59155259A (ja) * | 1983-02-23 | 1984-09-04 | 株式会社 ミドリ十字 | 腫瘍細胞除去用炉過器 |
| JPS62191612U (enExample) * | 1986-05-29 | 1987-12-05 | ||
| CA1339250C (en) * | 1988-03-21 | 1997-08-12 | Richard Calvin Ebersole | Method and apparatus for collecting and detecting microorganisms |
| US5089479A (en) * | 1988-11-28 | 1992-02-18 | Krivan Howard C | Adhesion of mycoplasma pneumoniae and mycoplasma hominus to sulfatide |
| JPH04207195A (ja) * | 1990-11-30 | 1992-07-29 | Shimadzu Corp | ウイルスの核酸成分採取方法及びウイルス検査法 |
| US5533512A (en) * | 1994-03-18 | 1996-07-09 | Ohmeda Inc. | Method and apparatus for detection of venous air emboli |
| WO1999022861A1 (en) * | 1997-11-05 | 1999-05-14 | Molecular Geodesics, Inc. | Biomimetic materials for filtration, chemical processing and detoxification |
| GB0001450D0 (en) | 2000-01-21 | 2000-03-08 | Genpoint As | Cell isolation method |
| WO2007013945A2 (en) * | 2005-07-20 | 2007-02-01 | The Regents Of The University Of California | Treating disorders associated with inflammation |
| WO2010078516A2 (en) * | 2009-01-01 | 2010-07-08 | Cornell University | Multifunctional nucleic acid nano-structures |
| JP5975000B2 (ja) | 2013-08-30 | 2016-08-23 | 株式会社ツムラ | 微生物検出方法 |
| AU2016212815B2 (en) * | 2015-01-26 | 2022-03-03 | Stichting Sanquin Bloedvoorziening | Methods and systems for the detection and removal of pathogens from blood |
| US20190060545A1 (en) * | 2016-03-08 | 2019-02-28 | Cytosorbents Corporation | The use of a hemocompatible porous polymer bead sorbent for removal of pamps and damps |
| WO2022146242A1 (en) * | 2020-12-29 | 2022-07-07 | Nanobi̇otech Arge İnovasyon Sağlik Ürünleri̇ Sanayi̇ Ve Ti̇caret Li̇mi̇ted Şi̇rketi̇ | Composition of a nanoparticle charged bioadsorbent blood culture and its production method |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2682268A (en) * | 1950-08-08 | 1954-06-29 | Abbott Lab | Venoclysis equipment |
| GB1339022A (en) * | 1970-09-18 | 1973-11-28 | American Cyanamid Co | Microbiological processes |
| US3803810A (en) * | 1972-05-01 | 1974-04-16 | Pall Corp | Liquid-gas separator and filter |
| GB1441022A (en) * | 1973-01-05 | 1976-06-30 | British Food Mfg Ind Res | Collection and measurement of microorganisms |
| US3928139A (en) * | 1973-02-12 | 1975-12-23 | Wadley Res Inst & Blood Bank | Detection of microbial pathogens |
| US3888250A (en) * | 1973-07-02 | 1975-06-10 | Becton Dickinson Co | Disposable hemoperfusion assembly for detoxification of blood and method therefor |
| GB1478971A (en) * | 1973-07-05 | 1977-07-06 | Univ Strathclyde | Solute-adsorptive material |
| US3875012A (en) * | 1974-01-30 | 1975-04-01 | Wadley Res Inst & Blood Bank | Apparatus and method for the detection of microbial pathogens |
| US3901808A (en) * | 1974-02-25 | 1975-08-26 | Gen Atomic Co | Blood filter |
| US3993560A (en) * | 1975-02-27 | 1976-11-23 | Halpern Richard M | Method and apparatus for monitoring cellular activities |
| US4083786A (en) * | 1975-03-20 | 1978-04-11 | Asahi Kasei Kogyo Kabushiki Kaisha | Apparatus for treating ascites |
| IL49752A (en) * | 1975-07-09 | 1979-07-25 | Kabi Ab | Compositions having affinity for hepatitis virus and method for hepatitis virus removal or concentration |
| DE2532941A1 (de) * | 1975-07-23 | 1977-02-10 | Hennecke Helmut Dr Sc Nat Dr R | Ligninhaltige substanzen als adsorbens bei biologischer anwendung |
| US4048064A (en) * | 1976-04-23 | 1977-09-13 | Clark Iii William T | Biocompatible hemoperfusion system |
-
1978
- 1978-08-16 SE SE7808686A patent/SE452336B/sv not_active IP Right Cessation
- 1978-08-18 AT AT0604778A patent/AT363610B/de not_active IP Right Cessation
- 1978-09-01 FI FI782696A patent/FI62138C/fi not_active IP Right Cessation
- 1978-09-01 JP JP10743678A patent/JPS5523986A/ja active Granted
- 1978-09-05 GB GB7835660A patent/GB2024421B/en not_active Expired
- 1978-09-13 BE BE190445A patent/BE870435A/xx not_active IP Right Cessation
- 1978-09-14 NL NL7809357A patent/NL7809357A/xx not_active Application Discontinuation
- 1978-09-18 IT IT27798/78A patent/IT1098837B/it active
- 1978-09-19 FR FR7826760A patent/FR2432048A1/fr active Granted
- 1978-09-20 CH CH9827/78A patent/CH654591A5/de not_active IP Right Cessation
- 1978-09-20 CH CH4058/85A patent/CH658376A5/de not_active IP Right Cessation
- 1978-10-02 DK DK435678A patent/DK153798C/da active
-
1979
- 1979-01-04 CA CA000319105A patent/CA1248435A/en not_active Expired
-
1980
- 1980-09-24 US US06/190,540 patent/US4543328A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US4543328A (en) | 1985-09-24 |
| FR2432048A1 (fr) | 1980-02-22 |
| FI62138B (fi) | 1982-07-30 |
| SE452336B (sv) | 1987-11-23 |
| CH658376A5 (de) | 1986-11-14 |
| DK153798B (da) | 1988-09-05 |
| AT363610B (de) | 1981-08-25 |
| CA1248435A (en) | 1989-01-10 |
| FR2432048B1 (enExample) | 1983-10-07 |
| DK435678A (da) | 1979-12-17 |
| GB2024421A (en) | 1980-01-09 |
| DK153798C (da) | 1989-01-23 |
| GB2024421B (en) | 1983-05-05 |
| ATA604778A (de) | 1981-01-15 |
| FI62138C (fi) | 1982-11-10 |
| JPS5743238B2 (enExample) | 1982-09-13 |
| IT1098837B (it) | 1985-09-18 |
| JPS5523986A (en) | 1980-02-20 |
| SE7808686L (sv) | 1979-12-17 |
| BE870435A (fr) | 1979-03-13 |
| NL7809357A (nl) | 1979-12-18 |
| FI782696A7 (fi) | 1979-12-17 |
| IT7827798A0 (it) | 1978-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH654591A5 (de) | Verfahren zum nachweis von erregern im blut. | |
| Tilton et al. | Differences in pericyte contractile function in rat cardiac and skeletal muscle microvasculatures | |
| DE69203828T2 (de) | Verfahren zur behandlung von produkten roter blutkörperchen zur langzeitlagerung frei von mikroorganismen. | |
| Neefe et al. | Disseminated strongyloidiasis with cerebral involvement: a complication of corticosteroid therapy | |
| JANEWAY et al. | Experiments on the vasoconstrictor action of blood serum | |
| EP3335744B1 (de) | Verfahren zum herstellen einer leukozytenpräparation und leukozytenpräparation | |
| CH626256A5 (en) | Device for the continuous, extracorporal separation of specific substances from blood | |
| DE2635065C2 (de) | Verfahren zur halbkontinuierlichen Behandlung von Gesamtblut zur Herstellung von biologisch aktiven hämatopoetischen Chalonextrakten | |
| DE2624815A1 (de) | Injizierbare, stromafreie haemoglobinloesung und verfahren zu ihrer herstellung | |
| Symmers | Opportunistic Infections: The Concept of ‘Opportunistic Infections’ | |
| EP0265690A2 (en) | Method and device for the determination of the presence of microorganisms in body liquors | |
| DE2857361C2 (de) | Verfahren zum Nachweis von Erregern im Blut | |
| Hildebrand et al. | Distribution and Particle Size of Type A Botulinum Toxin in Body Fluids of Intravenously Injected Rabbits. | |
| AT367795B (de) | Verfahren zum nachweis von erregern im blut | |
| Yan et al. | A new DNA immune adsorbent for hemoperfusion in SLE therapy: a clinical trial | |
| DE69016656T2 (de) | Vorrichtung zur inaktivierung infektioeser erreger und zur verhinderung der koagulierung in biologischen flüssigkeiten. | |
| Murray et al. | Artificial kidney | |
| DE7818078U1 (de) | Vorrichtung zum nachweis von erregern im blut | |
| DE2532883C2 (de) | Verfahren und Vorrichtung zur selektiven Gewinnung eines Reaktionspartners einer Immunreaktion aus dem strömenden Blut von lebenden Organismen | |
| Johnson | On the proximate cause of albuminous urine and dropsy, and on the pathology of the renal blood-vessels in Bright's Disease | |
| EP1744776B1 (de) | Wundheilungsfördernde botenstoffmischung | |
| Dewan et al. | Plastic particle migration during intravenous infusion assisted by a peristaltic finger pump in an animal model | |
| Bambauer et al. | Scanning electron microscopic investigations of large-bore catheters used for extracorporeal detoxification methods | |
| RU2099967C1 (ru) | Продукт, обладающий иммунокорригирующими свойствами | |
| Jakse et al. | Urethrography in urethral trauma: tissue reaction to extravasation of contrast dye and iatrogenic infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |